News
April 22, 2025
March Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of MB-105, First-in-Class CD5 CAR-T Cell Therapy for T-Cell Lymphoma
March Biosciences announced that the first patient has been dosed in its Phase 2 clinical trial evaluating MB-105, a first-in-class CD5-targeted CAR-T cell therapy for r/r T cell lymphoma
January 28, 2025
March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma
March Biosciences today announced that the FDA granted orphan drug designation to MB-105 ffor the treatment of relapsed / refractory CD5-positive T-cell lymphoma.
October 23, 2024
March Biosciences Closes Oversubscribed $28.4 Million Series A Financing
Mission BioCapital and 4BIO Capital led the financing with significant participation from new and existing investors to support Phase 2 development, raising over $51 million to date.
Publications
July 16, 2024
We demonstrate that the expression of a chimeric antigen receptor (CAR) targeting CD5, a prominent pan-T cell antigen, induces rapid internalization and complete loss of the CD5 protein on T cells, protecting them from self-targeting.
March 28, 2024
Phase 1 trial shows autologous CD5.CAR T cells are safe and effective in r/r T-cell lymphoma with a 44% overall response rate, promising advances in T-cell malignancy treatment.
June 2, 2023
We describe improved responses in T-ALL patients during a Phase I dose study (NCT03081910) of autologous CD5-directed chimeric antigen receptor T cell (CD5 CAR T) following the addition of tyrosine kinase inhibitors during manufacturing.